Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LySATRA
2022-500680-13-00Phase 2Authorised
- Sponsor
- Gustave Roussy
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tretinoin in Non-hematologic malignancy (2 arms), sponsored by Gustave Roussy. Primary endpoints: Part I safety and Part II efficacy on lymphoprotection. Planned start Mar 2024; status: authorised.
02
Drugs
tretinoin
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2022-500680-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500680-13-00.